DPV + LNG Vaginal Ring

Alternative Name: Dapivirine (DPV) + levonorgestrel (LNG) vaginal ring

Description: A silicone intravaginal ring (IVR) that a woman inserts and leaves in place for 90 days. The ring releases a combination of dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), to prevent HIV and levonorgestrel, a synthetic progestin, to prevent unintended pregnancy.

Product Details

User: Female

Hormonal: Yes

Delivery Method: Vaginal Ring

Duration Type: Short-acting

Duration: 90 days

Active Pharmaceutical Ingredient (API):
  • dapivirine
  • levonorgestrel

Inactive material: silicone

Multipurpose Preventive Technology (MPT): Yes

Status Details

Developer: International Partnership for Microbicides, USAID

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Phase I

Active Development: Yes

Status Details:
  • In collaboration with the NIH-funded Microbicide Trials Network (MTN), a U.S.-based Phase I trial was completed in August, 2017 and another phase I trial is currently underway.

Additional Information


Vertical Tabs